×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
DTIL – precision biosciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
DTIL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/12
08:55 am
dtil
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy [Yahoo! Finance]
Low
Report
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy [Yahoo! Finance]
1/12
07:01 am
dtil
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
Medium
Report
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
1/7
08:00 am
dtil
iECURE Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ECUR-506 for Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
Low
Report
iECURE Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ECUR-506 for Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
12/29
03:42 am
dtil
Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 [Seeking Alpha]
Low
Report
Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 [Seeking Alpha]
12/23
07:00 am
dtil
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
12/4
06:44 am
dtil
Precision Biosciences: Still Swinging And Finally Drawing Blood [Seeking Alpha]
Low
Report
Precision Biosciences: Still Swinging And Finally Drawing Blood [Seeking Alpha]
11/26
02:14 pm
dtil
Precision BioSciences (NASDAQ:DTIL) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Precision BioSciences (NASDAQ:DTIL) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
11/19
07:13 am
dtil
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 [Yahoo! Finance]
Medium
Report
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/3/2025
07:01 am
DTIL
precision biosciences, inc.
MISS
Report
-10.2%
precision biosciences, inc.
8/7/2025
07:01 am
DTIL
precision biosciences, inc.
MISS
Report
-8.6%
precision biosciences, inc.
5/15/2025
07:01 am
DTIL
precision biosciences, inc.
MISS
Report
-8.3%
precision biosciences, inc.
3/26/2025
07:01 am
DTIL
precision biosciences, inc.
MISS
Report
-15.5%
precision biosciences, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/13
04:12 pm
dtil
Form 8-K PRECISION BIOSCIENCES For: Jan 12
Low
Report
Form 8-K PRECISION BIOSCIENCES For: Jan 12
1/8
06:02 am
dtil
Form EFFECT PRECISION BIOSCIENCES
Medium
Report
Form EFFECT PRECISION BIOSCIENCES
12/30
08:05 am
dtil
Form S-3 PRECISION BIOSCIENCES
Medium
Report
Form S-3 PRECISION BIOSCIENCES
12/30
08:03 am
dtil
Form S-8 PRECISION BIOSCIENCES
Medium
Report
Form S-8 PRECISION BIOSCIENCES
12/17
07:02 am
dtil
Form 4 PRECISION BIOSCIENCES For: Dec 16 Filed by: Germano Geno J
Medium
Report
Form 4 PRECISION BIOSCIENCES For: Dec 16 Filed by: Germano Geno J
12/17
07:01 am
dtil
Form 4 PRECISION BIOSCIENCES For: Dec 15 Filed by: Brown Melinda
Medium
Report
Form 4 PRECISION BIOSCIENCES For: Dec 15 Filed by: Brown Melinda
12/17
07:01 am
dtil
Form 4 PRECISION BIOSCIENCES For: Dec 16 Filed by: Frankel Stanley
Medium
Report
Form 4 PRECISION BIOSCIENCES For: Dec 16 Filed by: Frankel Stanley
11/14
02:02 pm
dtil
Form SCHEDULE 13G/A PRECISION BIOSCIENCES Filed by: Lynx1 Capital Management LP
Low
Report
Form SCHEDULE 13G/A PRECISION BIOSCIENCES Filed by: Lynx1 Capital Management LP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/13
Precision BioSciences Inc (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
24.6%
4/6 Form 8-K PRECISION BIOSCIENCES For: Apr 06 21.4%
11/6 Precision BioSciences Announces the Presentation of Initial Clinical Data Supporting the Safety and Clinical Activity of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate, at the American Society of Hematology Annual Meeting 18.6%
1/8 Form 4 PRECISION BIOSCIENCES For: Jan 06 Filed by: ANSARI ABID 17.3%
3/12 Form 3 PRECISION BIOSCIENCES For: Mar 10 Filed by: Germano Geno J 13.8%
4/28 Precision BioSciences Announces Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting 6.8%
4/8 Precision BioSciences Inc (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock. 6.4%
11/12 Form 10-Q PRECISION BIOSCIENCES For: Sep 30 5.7%
2/24 Precision BioSciences: Consider Taking Up A Small Position [Seeking Alpha] 5.4%
11/13 Form 3 PRECISION BIOSCIENCES For: Nov 08 Filed by: Buehler Kevin 5.3%
4/6 Form 8-K PRECISION BIOSCIENCES For: Apr 06 21.4%
11/6 Precision BioSciences Announces the Presentation of Initial Clinical Data Supporting the Safety and Clinical Activity of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate, at the American Society of Hematology Annual Meeting 18.6%
1/8 Form 4 PRECISION BIOSCIENCES For: Jan 06 Filed by: ANSARI ABID 17.3%
3/12 Form 3 PRECISION BIOSCIENCES For: Mar 10 Filed by: Germano Geno J 13.8%
4/28 Precision BioSciences Announces Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting 6.8%
4/8 Precision BioSciences Inc (NASDAQ: DTIL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock. 6.4%
11/12 Form 10-Q PRECISION BIOSCIENCES For: Sep 30 5.7%
2/24 Precision BioSciences: Consider Taking Up A Small Position [Seeking Alpha] 5.4%
11/13 Form 3 PRECISION BIOSCIENCES For: Nov 08 Filed by: Buehler Kevin 5.3%
TOP News Decliners
12/9
Precision BioSciences stock rises on early-stage CAR-T trial data [MarketWatch]
-54.5%
3/12 Form 8-K PRECISION BIOSCIENCES For: Mar 12 -16.5%
4/15 Precision Biosciences Appoints Dora Alvarado as Senior Vice President of Human Resources -16.4%
8/9 Precision BioSciences Inc (NASDAQ: DTIL) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock. -16.3%
4/2 Precision BioSciences Inc (NASDAQ: DTIL) was downgraded by analysts at Goldman Sachs Group Inc from a "buy" rating to a "neutral" rating. -15.9%
3/11 Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano -14.6%
1/15 Form 8-K/A PRECISION BIOSCIENCES For: Jan 15 -12.4%
1/13 Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma -8.0%
9/25 Form 4 PRECISION BIOSCIENCES For: Sep 23 Filed by: KANE MATTHEW R. -7.7%
2/7 Form SC 13G PRECISION BIOSCIENCES Filed by: BlackRock Inc. -7.1%
3/12 Form 8-K PRECISION BIOSCIENCES For: Mar 12 -16.5%
4/15 Precision Biosciences Appoints Dora Alvarado as Senior Vice President of Human Resources -16.4%
8/9 Precision BioSciences Inc (NASDAQ: DTIL) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock. -16.3%
4/2 Precision BioSciences Inc (NASDAQ: DTIL) was downgraded by analysts at Goldman Sachs Group Inc from a "buy" rating to a "neutral" rating. -15.9%
3/11 Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano -14.6%
1/15 Form 8-K/A PRECISION BIOSCIENCES For: Jan 15 -12.4%
1/13 Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma -8.0%
9/25 Form 4 PRECISION BIOSCIENCES For: Sep 23 Filed by: KANE MATTHEW R. -7.7%
2/7 Form SC 13G PRECISION BIOSCIENCES Filed by: BlackRock Inc. -7.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: